CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) indication: ankylosing spondylitis
The CADTH Canadian Drug Expert Committee (CDEC) recommends that ixekizumab be reimbursed for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to, or are intolerant to conventional therapy only if the following conditions are met
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
CADTH
March 2020, 2020
|
| Edition: | Version 1.0 |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that ixekizumab be reimbursed for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to, or are intolerant to conventional therapy only if the following conditions are met |
|---|---|
| Physical Description: | 1 PDF file (10 pages) |